Explainable MMM for Pharma: Questions to Ask a Model Vendor
What makes a marketing mix model explainable for pharma, questions to ask MMM vendors, open-source options, calibration, and red flags.
The short answer
An explainable marketing mix model shows how it reached its recommendations: the data and transformations used, the assumptions about carryover and diminishing returns, how uncertain each channel estimate is, how results were checked against experiments, and why the optimizer moved budget. For pharma, ask vendors how they handle HCP and DTC channels, field force, competitive and access effects, data lags, and calibration with holdouts.
Marketing mix models produce confident budget recommendations. Some deserve that confidence. Others are fragile models with polished outputs. Explainability is how you tell the difference before moving millions of dollars.
What explainable means
- Inputs. Which data, at what level, over what period.
- Transformations. How carryover (adstock) and diminishing returns (saturation) are modeled.
- Controls. Which non-marketing factors are included: access, seasonality, competitors, field force.
- Uncertainty. Ranges for each channel's contribution, not just point estimates.
- Validation. How results compare with experiments and holdout periods.
- Optimization logic. Why the recommended budget follows from the curves.
Pharma-specific questions
| Topic | Question |
|---|---|
| HCP vs. DTC | Are HCP and DTC channels modeled with separate outcome paths? |
| Field force | How are rep calls included, and how is their effect separated from media? |
| Access | How are formulary and coverage changes handled? |
| Data lag | How are prescription data lags handled? |
| Granularity | National, regional, or HCP-level data? |
| Small brands | How do you handle limited data for rare-disease brands? |
Calibration with experiments
Models can produce plausible but wrong estimates, especially when channels move together over time. Calibration uses experiment results, such as holdouts or geo tests, to anchor channel estimates. Ask:
- Which experiments were used?
- How much did calibration change results?
- What happens to recommendations without calibration?
Google's open-source Meridian explicitly supports calibration with experiment priors.
Red flags
- No uncertainty ranges.
- Channel estimates that swing widely between model runs.
- Recommendations to move most budget into one channel.
- No validation on a holdout period.
- Unwilling to share assumptions.
Open-source vs. vendor platforms
| Open source | Vendor platform | |
|---|---|---|
| Transparency | Full code visibility | Varies |
| Pharma specifics | You build them | May be built in |
| Cost | Staff time | License and services |
| Support | Community | Vendor |
Many brands use vendors for production and open-source tools to sanity-check results.
Using results
- Use response curves to move budget at the margin.
- Re-run quarterly with new data.
- Plan experiments where estimates are most uncertain.
See promotional response curves and MMM vs. Rx attribution.
Practical takeaway
Ask your MMM provider to show each channel's estimate with and without experiment calibration, plus the uncertainty range. If they cannot, treat budget recommendations as hypotheses to test, not instructions.
Frequently asked questions
What is marketing mix modeling in pharma?
A statistical model that estimates how each marketing channel, plus factors like field force, access, and seasonality, contributes to prescriptions or sales over time.
What makes an MMM explainable?
Transparent inputs, assumptions, uncertainty, validation against experiments, and a clear account of why recommendations follow from the model.
Are open-source MMM tools usable in pharma?
Yes, tools such as Google's Meridian and Meta's Robyn can be adapted, but pharma data, such as HCP-level promotion and access changes, needs careful setup.
Sources
- Google for Developers, Meridian (open-source MMM with experiment calibration)
- Meta Open Source, Robyn (GitHub)
- American Statistical Association, Statement on p-Values
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.